Appeal Court legitimize FAS refusal to register overrated prices for medicinal drugs
On 5 July 2016, the 9th Arbitration Appeal Court upheld the judgment of Moscow Arbitration Court and pronounced legitimacy of the refusal of the Federal Antimonopoly Service (FAS Russia) to approve the maximum ex-works prices for “Ciprofloxacin” and “Metronidazole” medicinal drugs made by “Elfa Laboratories” (India) upon a petition of “Elfa” Research-and-Production Centre” JSC.
As the antimonopoly authority reported earlier, the reason behind the FAS refusal was that prices submitted for government registration unreasonably exceeded the earlier registered prices: more than threefold for “Ciprofloxacin” and more than fourfold for “Metronidazole” when the number of vials per package increased.
“Elfa” Research-and-Production Centre” JSC did not submit evidence to the Appeal Court justifying such a high growth of prices for medicinal drugs.
“The ruling of the Arbitration Court came into force. We were able to confirm the correctness of the findings of an economic analysis carried out by FAS and the conclusions made by the antimonopoly body that the prices for medicinal drugs were overrated unreasonably”, pointed out Deputy Head of FAS Department for Control over Social Sphere and Trade, Mikhail Degtyaryov.